Skip to content
2000
image of The Pharmacoeconomics and its Evaluation in Enhancing the Indian Healthcare System

Abstract

Introduction

Escalating healthcare costs and increasing demands on healthcare systems have increased the need for efficient resource allocation. Pharmacoeconomics is a vital field that quantifies and compares the value of therapeutic drugs or treatments. It provides a systematic framework for decision-makers in the pharmaceutical industry, government, and private sectors to optimize healthcare delivery and spending. This review aimed to explore the role of pharmacoeconomic models in assessing the economic and clinical value of therapies. It emphasizes the importance of cost-effectiveness, cost-utility, cost-benefit, and cost-minimization analyses in balancing costs with outcomes and guiding healthcare resource allocation.

Methods

Pharmacoeconomic methodologies focus on assessing the costs, processes, and outcomes associated with therapeutic interventions. Key methods include cost-minimization, cost-effectiveness, cost-utility, and cost-benefit analyses. These approaches are critical in regulatory compliance, reimbursement decisions, cost assessments, and sustaining pharmaceutical models.

Results

This review reveals that pharmacoeconomic approaches such as Cost-Effectiveness Analysis (CEA), Cost-Utility Analysis (CUA), and Cost-Benefit Analysis (CBA) are widely used to guide healthcare policy decisions, particularly in resource-constrained settings. CEA is the most commonly applied method due to its simplicity, while CUA is gaining traction in advanced policy frameworks like Health Technology Assessment (HTA). In India, pharmacoeconomic research is emerging but faces barriers such as limited access to real-world data, the absence of national reimbursement systems, and high out-of-pocket costs. Innovative methods like machine learning and pharmacogenomics are being explored to improve the relevance and precision of these evaluations.

Discussion

While pharmacoeconomic models offer valuable insights for healthcare decision-making, their real-world impact is limited by inconsistencies in data quality and variations in implementation standards. In India, fragmented governance, low public health spending, and a lack of coordination among stakeholders further hinder effective application. Addressing systemic challenges-such as establishing interoperable data systems, standard treatment guidelines, and equitable healthcare access-is crucial. Tailored approaches, including localized utility values and digital health initiatives, are essential to make pharmacoeconomics a practical and influential tool in policy formulation and resource allocation in India and similar settings.

Conclusion

Pharmacoeconomic studies evaluate clinical efficacy, adverse effects, and production costs while incorporating perspectives from patients, providers, payers, and communities. For India, unique challenges such as limited rural healthcare access, infrastructure disparities, and high out-of-pocket expenses necessitate tailored adaptations. Strategies such as integrating accessibility metrics, localized data, equity considerations, preventive care, tiered pricing, and public-private partnerships can enhance healthcare delivery. Pharmacoeconomic models are essential for improving health outcomes, ensuring equitable resource allocation, and addressing the diverse needs of India.

Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775394503250626070441
2025-07-04
2025-10-15
Loading full text...

Full text loading...

References

  1. Arenas-Guzman R Tosti A Hay R Haneke E. Pharmacoeconomics – An aid to better decision‐making J Eur Acad Dermatol Venereol 2005 19 s1 34 9 (Suppl. 1) 10.1111/j.1468‑3083.2005.01285.x 16120204
    [Google Scholar]
  2. Tonin F.S. Aznar-Lou I. Pontinha V.M. Pontarolo R. Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm. Pract. 2021 19 1 2302 10.18549/PharmPract.2021.1.2302 33727994
    [Google Scholar]
  3. Davies B. Responsibility and the limits of patient choice. Bioethics 2020 34 5 459 466 10.1111/bioe.12693 31770814
    [Google Scholar]
  4. Humphreys P. Spratt B. Tariverdi M. An overview of hospital capacity planning and optimisation. Health Care 2022 10 5 826 10.3390/healthcare10050826 35627963
    [Google Scholar]
  5. Picot J. Jones J. Colquitt J.L. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: A systematic review and economic evaluation. Health Technol. Assess. 2009 13 41 1 190, 215-357 [iii-iv. 10.3310/hta13410 19726018
    [Google Scholar]
  6. Loveman E. Frampton G.K. Shepherd J. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: A systematic review. Health Technol. Assess. 2011 15 2 1 182 10.3310/hta15020 21247515
    [Google Scholar]
  7. Rodziewicz T.L. Houseman B. Vaqar S. Medical Error Reduction and Prevention. Treasure Island, FL StatPearls Publishing 2025
    [Google Scholar]
  8. Ahmad A. Chang J. Chung H.C. Mohanta G. Parimilakrishnan S. Patel I. The role of pharmacoeconomics in current Indian healthcare system. J. Res. Pharm. Pract. 2013 2 1 3 9 10.4103/2279‑042X.114081 24991597
    [Google Scholar]
  9. Satya Durga K. Sowmya N. Charishma S. Sharmila Nirojini P. A pharmacoeconomic study and its appraisal in improving health care outcomes in patients suffering from type-2 diabetes among rural areas in South-East India. Int. J. Adv. Res. 2017 5 890 901 10.21474/IJAR01/6035
    [Google Scholar]
  10. Thwaites R. Townsend R.J. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective. PharmacoEconomics 1998 13 2 175 180 10.2165/00019053‑199813020‑00002 10178645
    [Google Scholar]
  11. Reeder CE Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. Am J Health Syst Pharm 1995 52 19 S5 8 (Suppl. 4) 10.1093/ajhp/52.19_Suppl_4.S5 8846244
    [Google Scholar]
  12. Bodrogi J. Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br. J. Pharmacol. 2010 159 7 1367 1373 10.1111/j.1476‑5381.2009.00550.x 20132213
    [Google Scholar]
  13. Thomas R. Chalkidou K. Health system efficiency: How to make measurement matter for policy and management. In:Cost–effectiveness analysis. Copenhagen, Denmark European Observatory on Health Systems and Policies 2016
    [Google Scholar]
  14. Fan C. Song X. Li C. The relationship between health insurance and pharmaceutical innovation: An empirical study based on meta-analysis. Health Care 2023 11 22 2916 10.3390/healthcare11222916 37998407
    [Google Scholar]
  15. Langley P.C. Sullivan S.D. Pharmacoeconomic evaluations: Guidelines for drug purchasers. J. Manag. Care Spec. Pharm. 2020 26 6 689 695 10.18553/jmcp.2020.26.6.689 32463775
    [Google Scholar]
  16. Freund D.A. Dittus R.S. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1992 1 1 20 32 10.2165/00019053‑199201010‑00006 10147037
    [Google Scholar]
  17. Drummond M. Jönsson B. Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997 40 3 199 215 10.1016/S0168‑8510(97)00901‑9 10168752
    [Google Scholar]
  18. Hussey P.S. Wertheimer S. Mehrotra A. The association between health care quality and cost: A systematic review. Ann. Intern. Med. 2013 158 1 27 34 10.7326/0003‑4819‑158‑1‑201301010‑00006 23277898
    [Google Scholar]
  19. Gold H.T. McDermott C. Hoomans T. Wagner T.H. Cost data in implementation science: Categories and approaches to costing. Implement. Sci. 2022 17 1 11 10.1186/s13012‑021‑01172‑6 35090508
    [Google Scholar]
  20. Shi N. Foley K. Lenhart G. Badamgarav E. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 2009 45 6 1084 1090 10.1016/j.bone.2009.07.086 19664735
    [Google Scholar]
  21. Stahl J.E. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. PharmacoEconomics 2008 26 2 131 148 10.2165/00019053‑200826020‑00004 18198933
    [Google Scholar]
  22. Kozma C.M. Reeder C.E. Schulz R.M. Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research. Clin. Ther. 1993 15 6 1121 1132 [PMID: 8111809
    [Google Scholar]
  23. Prinja S. Chauhan A.S. Angell B. Gupta I. Jan S. A systematic review of the state of economic evaluation for health care in India. Appl. Health Econ. Health Policy 2015 13 6 595 613 10.1007/s40258‑015‑0201‑6 26449485
    [Google Scholar]
  24. Hughes D.A. An agenda for UK clinical pharmacology: Pharmacoeconomics. Br. J. Clin. Pharmacol. 2012 73 6 968 972 10.1111/j.1365‑2125.2012.04247.x 22360714
    [Google Scholar]
  25. Revicki D.A. Luce B.R. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol. Bull. 1995 31 1 57 65 [PMID: 7675990
    [Google Scholar]
  26. Drummond M.F. Stoddart G.L. Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed Oxford Oxford University Press 1997
    [Google Scholar]
  27. Sacristán J.A. Soto J. Galende I. Evaluation of pharmacoeconomic studies: Utilization of a checklist. Ann. Pharmacother. 1993 27 9 1126 1133 10.1177/106002809302700919 8219449
    [Google Scholar]
  28. Haycox A. Walley T. Pharmacoeconomics: Evaluating the evaluators. Br. J. Clin. Pharmacol. 1997 43 5 451 456 10.1046/j.1365‑2125.1997.00575.x 9159558
    [Google Scholar]
  29. Jolicoeur L.M. Jones-Grizzle A.J. Boyer J.G. Guidelines for performing a pharmacoeconomic analysis. Am. J. Hosp. Pharm. 1992 49 7 1741 1747 [PMID: 1621734
    [Google Scholar]
  30. Longo CJ Choices of methodology in pharmacoeconomics studies. Med Care 1999 37 (4 Suppl Lilly) AS32 5 10.1097/00005650‑199904001‑00006 10217391
    [Google Scholar]
  31. Plumridge R.J. Wojnar-Horton R.E. A review of the pharmacoeconomics of pharmaceutical care. PharmacoEconomics 1998 14 2 175 189 10.2165/00019053‑199814020‑00006 10186458
    [Google Scholar]
  32. Walley T. Haycox A. Pharmacoeconomics: Basic concepts and terminology. Br. J. Clin. Pharmacol. 1997 43 4 343 348 10.1046/j.1365‑2125.1997.00574.x 9146844
    [Google Scholar]
  33. Mullins C.D. Wang J. Pharmacy benefit management: Enhancing the applicability of pharmacoeconomics for optimal decision making. PharmacoEconomics 2002 20 1 9 21 10.2165/00019053‑200220010‑00002 11817989
    [Google Scholar]
  34. Duggal R. Healthcare in India: Changing the financing strategy. Soc. Policy Adm. 2007 41 4 386 394 10.1111/j.1467‑9515.2007.00560.x
    [Google Scholar]
  35. Kumar R. Duggirala A. Health insurance as a healthcare financing mechanism in India: Key strategic insights and a business model perspective. Vikalpa 2021 46 2 112 128 10.1177/02560909211027089
    [Google Scholar]
  36. Kumar A. The transformation of the indian healthcare system. Cureus 2023 15 5 39079 10.7759/cureus.39079 37378105
    [Google Scholar]
  37. Balarajan Y. Selvaraj S. Subramanian S.V. Health care and equity in India. Lancet 2011 377 9764 505 515 10.1016/S0140‑6736(10)61894‑6 21227492
    [Google Scholar]
  38. Kadarpeta R.S.R. Anand J.S. Achungura G. Strengthening public financing of primary healthcare in India: A perspective. Health Serv. Insights 2024 17 11786329241249289 10.1177/11786329241249289 38737570
    [Google Scholar]
  39. Bose M. Dutta A. Health financing strategies to reduce out-of-pocket burden in India: A comparative study of three states. BMC Health Serv. Res. 2018 18 1 830 10.1186/s12913‑018‑3633‑5 30390701
    [Google Scholar]
  40. Maurya D. Asher M. Sustainable health financing system for India: The economic perspective. Natl. Med. J. India 2021 34 2 95 99 10.4103/0970‑258X.326759 34599122
    [Google Scholar]
  41. Hendrix N. Kwete X. Bolongaita S. Economic evaluations of health system strengthening activities in low-income and middle-income country settings: A methodological systematic review. BMJ Glob. Health 2022 7 3 007392 10.1136/bmjgh‑2021‑007392 35277429
    [Google Scholar]
  42. Tarn YH Hu S Kamae I Health-care systems and pharmacoeconomic research in Asia-Pacific region. Value Health 2008 11 S137 55 (Suppl. 1) 10.1111/j.1524‑4733.2008.00378.x 18387058
    [Google Scholar]
  43. Agrawal S.B. Health technology assessment in India: Present status and future perspectives. J. Adv. Pharm. Educ. Res. 2014 4 1 13 19
    [Google Scholar]
  44. Parthasarathi G. Nyfort-Hansen K. Nahata M.C. A Textbook of Clinical Pharmacy Practice, Essential Concepts and Skills. Orient Blackswan 2007
    [Google Scholar]
  45. McGhan W.F. Rowland C.R. Bootman J.L. Cost-benefit and cost-effectiveness: Methodologies for evaluating innovative pharmaceutical services. Am. J. Health Syst. Pharm. 1978 35 2 133 140 10.1093/ajhp/35.2.133 415603
    [Google Scholar]
  46. Lyle Bootman J. Wertheimer A.I. Zaske D. Rowland C. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: A cost--benefit analysis. J. Pharm. Sci. 1979 68 3 267 272 10.1002/jps.2600680304 106108
    [Google Scholar]
  47. Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical benefits advisory committee. 1992 Available from:www.health.gov.au/pbs/pharm/pubs/guidelines/content.htm
  48. Drug and Therapeutic Committees A practical guide, managing the formulary process. 2003 Available from:http://www.apps.who.int/medicinedocs/en/d/Js4882e/5.html
    [Google Scholar]
  49. Trude S. Au M. Christianson J.B. Health plan pay-for-performance strategies. Am. J. Manag. Care 2006 12 9 537 542 [PMID: 16961442
    [Google Scholar]
  50. Jadaun G.P.S. Rastogi S. Kumar A. Ensuring the quality of medicines in India: An update on the development, modernization, and harmonization of drug standards in the Indian Pharmacopoeia. Saudi Pharm. J. 2023 31 12 101825 10.1016/j.jsps.2023.101825 37965488
    [Google Scholar]
  51. Tenni B. Moir H.V.J. Townsend B. What is the impact of intellectual property rules on access to medicines? A systematic review. Global. Health 2022 18 1 40 10.1186/s12992‑022‑00826‑4 35428250
    [Google Scholar]
  52. Park Y. Raza S. George A. Agrawal R. Ko J. The effect of formulary restrictions on patient and payer outcomes: A systematic literature review. J. Manag. Care Spec. Pharm. 2017 23 8 893 901 10.18553/jmcp.2017.23.8.893 28737993
    [Google Scholar]
  53. Parrish R.H. Lecture 2—What is a formulary, anyway? (or the cliff notes version of drug stewardship and expense control). Pharmacy 2018 6 3 69 10.3390/pharmacy6030069 30036933
    [Google Scholar]
  54. Alzarea A.I. Khan Y.H. Alanazi A.S. Barriers and facilitators of pharmacoeconomic studies: A review of evidence from the middle eastern countries. Int. J. Environ. Res. Public Health 2022 19 13 7862 10.3390/ijerph19137862 35805521
    [Google Scholar]
  55. Walt G. Shiffman J. Schneider H. Murray S.F. Brugha R. Gilson L. ‘Doing’ health policy analysis: Mthodological and conceptual reflections and challenges. Health Policy Plan. 2008 23 5 308 317 10.1093/heapol/czn024 18701552
    [Google Scholar]
  56. IInstitute of Medicine (US) Committee on the Social and Ethical Impacts of Developments in Biomedicine 1995 Available from: https://www.ncbi.nlm.nih.gov/books/NBK231979/
  57. Health policy and management Wikipedia, The Free Encyclopedia. 2023 Availbale from: https://en.wikipedia.org/w/index.php?title=Health_policy_and_management&oldid=1184041095
    [Google Scholar]
  58. Ojha A. Ojha U. Ojha H. Role of AYUSH therapies in modern medicine: A qualitative study to explore the awareness and attitudes of doctors towards the utilization of alternate system of medicine for diabetes mellitus. Int. J. Gen. Med. 2020 13 1 8 10.2147/IJGM.S220444 32021386
    [Google Scholar]
  59. Milewska S. Niemirowicz-Laskowska K. Siemiaszko G. Nowicki P. Wilczewska A.Z. Car H. Current trends and challenges in pharmacoeconomic aspects of nanocarriers as drug delivery systems for cancer treatment. Int. J. Nanomedicine 2021 16 6593 6644 10.2147/IJN.S323831 34611400
    [Google Scholar]
  60. Rusmawantia D.A. Wijaya H. Citraningtyas G. Al-Mubarak A. Pharmacists’ knowledge of non-sterile good compounding practice (GCP) and its implementation in balikpapan community health centers: A cross-sectional study. Malays J Med Res 2025 9 1 11 21 10.31674/mjmr.2025.v09i01.002
    [Google Scholar]
  61. Johnson S.G. Simon G. Aliferis C. Artificial Intelligence and Machine Learning in Health Care and Medical Sciences: Best Practices and Pitfalls. Cham, CH Springer 2024 659 692 10.1007/978‑3‑031‑39355‑6_16
    [Google Scholar]
  62. McCombs J. Pharmacoeconomics: What is it and where is it going? Am. J. Hypertens. 1998 11 3 112S 119S 10.1016/S0895‑7061(98)00108‑3 9717852
    [Google Scholar]
  63. D’Errico C.C. Pharmacoeconomics analysis in a pediatric population. Ann. Thorac. Surg. 1998 65 6 S52 S55 [Suppl. 10.1016/S0003‑4975(98)00331‑2 9647139
    [Google Scholar]
  64. Zheng Y. Pan F. Sorensen S. Modeling treatment sequences in pharmacoeconomic models. PharmacoEconomics 2017 35 1 15 24 10.1007/s40273‑016‑0455‑3 27722894
    [Google Scholar]
  65. Carta A. Conversano C. On the use of markov models in pharmacoeconomics: Pros and cons and implications for policy makers. Front. Public Health 2020 8 569500 10.3389/fpubh.2020.569500 33194969
    [Google Scholar]
  66. Briggs A. Sculpher M. An introduction to Markov modelling for economic evaluation. PharmacoEconomics 1998 13 4 397 409 10.2165/00019053‑199813040‑00003 10178664
    [Google Scholar]
  67. Welsing P.M.J. Severens J.L. Hartman M. van Gestel A.M. van Riel P.L.C.M. Laan R.F.J.M. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. PharmacoEconomics 2006 24 10 1011 1020 10.2165/00019053‑200624100‑00008 17002483
    [Google Scholar]
  68. Nuijten M.J.C. van Iperen P. Palmer C. van Hilten B.J. Snyder E. Cost-effectiveness analysis of entacapone in Parkinson’s disease: A Markov process analysis. Value Health 2001 4 4 316 328 10.1046/j.1524‑4733.2001.004004316.x 11705299
    [Google Scholar]
  69. Polak S. Skowron A. Mendyk A. Brandys J. Artificial neural network in pharmacoeconomics. Stud. Health Technol. Inform. 2004 105 241 249 [PMID: 15718613
    [Google Scholar]
  70. Yagudina R. Kulikov A. Serpik V. Borodin A. Vygodchikova I. Patient flows, patient distribution computations and medicines accounting in the pharmacoeconomic models through procurement perspective. Clinicoecon. Outcomes Res. 2021 13 673 680 10.2147/CEOR.S312986 34326653
    [Google Scholar]
  71. Miller P. Role of pharmacoeconomic analysis in R&D decision making: When, where, how? PharmacoEconomics 2005 23 1 1 12 10.2165/00019053‑200523010‑00001 15693724
    [Google Scholar]
  72. van Baal P. Meltzer D. Brouwer W. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al. PharmacoEconomics 2013 31 5 369 373 10.1007/s40273‑013‑0042‑9 23595557
    [Google Scholar]
  73. Agro K.E. Bradley C.A. Mittmann N. Iskedjian M. Ilersich A.L. Einarson T.R. Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature. PharmacoEconomics 1997 11 1 75 88 10.2165/00019053‑199711010‑00009 10165529
    [Google Scholar]
  74. Jain R. Grabner M. Onukwugha E. Sensitivity analysis in cost-effectiveness studies: From guidelines to practice. PharmacoEconomics 2011 29 4 297 314 10.2165/11584630‑000000000‑00000 21395350
    [Google Scholar]
  75. Bae S. Lee J. Bae E.Y. How sensitive is sensitivity analysis?: Evaluation of pharmacoeconomic submissions in Korea. Front. Pharmacol. 2022 13 884769 10.3389/fphar.2022.884769 35652044
    [Google Scholar]
  76. Briggs A. Sculpher M. Sensitivity analysis in economic evaluation: A review of published studies. Health Econ. 1995 4 5 355 371 10.1002/hec.4730040502 8563834
    [Google Scholar]
  77. Nuijten M.J.C. Hardens M. Measuring sensitivity in pharmacoeconomic studies. An integration of point-sensitivity and range-sensitivity. PharmacoEconomics 1997 12 5 555 564 10.2165/00019053‑199712050‑00006 10174322
    [Google Scholar]
  78. Vreman R.A. Geenen J.W. Knies S. Mantel-Teeuwisse A.K. Leufkens H.G.M. Goettsch W.G. The application and implications of novel deterministic sensitivity analysis methods. PharmacoEconomics 2021 39 1 1 17 10.1007/s40273‑020‑00979‑3 33313990
    [Google Scholar]
  79. Wani N.U. Taneja K. Adlakha N. Health system in India: Opportunities and challenges for enhancements. IOSR J. Bus. Manag. 2013 9 2 74 82
    [Google Scholar]
  80. Morgan S Thomson PA Daw JR Friesen MK Dijkstra A The public provision of pharmaceuticals: A synthesis of policies in ten developed countries.
    [Google Scholar]
  81. Koopmanschap M.A. Rutten F.F.H. The impact of indirect costs on outcomes of health care programs. Health Econ. 1994 3 6 385 393 10.1002/hec.4730030606 9435921
    [Google Scholar]
  82. Fusco N. Sils B. Graff J.S. Kistler K. Ruiz K. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review. J. Manag. Care Spec. Pharm. 2023 29 1 4 16 10.18553/jmcp.2022.21270 35389285
    [Google Scholar]
  83. Martin S. Rice N. Smith P.C. Comparing costs and outcomes across programmes of health care. Health Econ. 2012 21 3 316 337 10.1002/hec.1716 21322086
    [Google Scholar]
  84. Lavtepatil S. Ghosh S. Improving access to medicines by popularising generics: A study of ‘India’s People’s Medicine’ scheme in two districts of Maharashtra. BMC Health Serv. Res. 2022 22 1 643 10.1186/s12913‑022‑08022‑1 35562697
    [Google Scholar]
  85. Charan J. Saxena D. Chaudhri M. Dutta S. Kaur R.J. Bhardwaj P. Opinion of primary care physicians regarding prescription of generic drugs. J. Family Med. Prim. Care 2021 10 3 1390 1398 10.4103/jfmpc.jfmpc_2157_20 34041184
    [Google Scholar]
  86. Li R. Zhang P. Barker L.E. Chowdhury F.M. Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010 33 8 1872 1894 10.2337/dc10‑0843 20668156
    [Google Scholar]
  87. Anawade P.A. Sharma D. Gahane S. A comprehensive review on exploring the impact of telemedicine on healthcare accessibility. Cureus 2024 16 3 55996 10.7759/cureus.55996 38618307
    [Google Scholar]
  88. Gizaw Z. Astale T. Kassie G.M. What improves access to primary healthcare services in rural communities? A systematic review. BMC Primary Care 2022 23 1 313 10.1186/s12875‑022‑01919‑0 36474184
    [Google Scholar]
  89. Ghia C. Rambhad G. Implementation of equity and access in Indian healthcare: Current scenario and way forward. J. Mark. Access Health Policy 2023 11 1 2194507 10.1080/20016689.2023.2194507 36998432
    [Google Scholar]
  90. Mohanty S.K. Upadhyay A.K. Maiti S. Public health insurance coverage in India before and after PM-JAY: Repeated cross-sectional analysis of nationally representative survey data. BMJ Glob. Health 2023 8 8 012725 10.1136/bmjgh‑2023‑012725 37640493
    [Google Scholar]
  91. Grewal H. Sharma P. Dhillon G. Munjal R.S. Verma R.K. Kashyap R. Universal health care system in India: An in-depth examination of the Ayushman Bharat initiative. Cureus 2023 15 6 40733 10.7759/cureus.40733 37485096
    [Google Scholar]
  92. Hollingworth S.A. Leaupepe G.A. Nonvignon J. Fenny A.P. Odame E.A. Ruiz F. Economic evaluations of non-communicable diseases conducted in Sub-Saharan Africa: A critical review of data sources. Cost Eff. Resour. Alloc. 2023 21 1 57 10.1186/s12962‑023‑00471‑7 37641087
    [Google Scholar]
  93. Rao K.D. Mehta A. Kautsar H. Improving quality of non-communicable disease services at primary care facilities in middle-income countries: A scoping review. Soc. Sci. Med. 2023 320 115679 10.1016/j.socscimed.2023.115679 36731302
    [Google Scholar]
  94. Dubois D.J. Grand challenges in pharmacoeconomics and health outcomes. Front. Pharmacol. 2010 1 7 10.3389/fphar.2010.00007 21713104
    [Google Scholar]
  95. Thomas D. Zachariah S. Reddy Y.P. Alvarez-Uria G. Development of pharmacoeconomics guidelines for India. Perspect. Clin. Res. 2014 5 2 91 10.4103/2229‑3485.128030 24741488
    [Google Scholar]
  96. Yang J. Wei Q. Yang X. Jiao J. Yang Z. Li F. Assessment and predictive analysis of health professions students’ proficiency in health economics and pharmacoeconomics in Southwest China: A cross-sectional study. BMC Med. Educ. 2024 24 1 1239 10.1186/s12909‑024‑06214‑3 39482631
    [Google Scholar]
  97. Girardin F.R. Cohen K. Schwenkglenks M. Durand-Zaleski I. Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment. Front. Pharmacol. 2023 14 1210002 10.3389/fphar.2023.1210002 37261286
    [Google Scholar]
  98. Bennett C.C. Hauser K. Artificial intelligence framework for simulating clinical decision-making: A Markov decision process approach. Artif. Intell. Med. 2013 57 1 9 19 10.1016/j.artmed.2012.12.003 23287490
    [Google Scholar]
  99. Fleurence R Wang X Bian J Generative AI in Health Economics and Outcomes Research: A Taxonomy of Key Definitions and Emerging Applications, an ISPOR Working Group Report. 2024
    [Google Scholar]
  100. Kapoor A Sharma R Innovations in pharmacoeconomic modeling: New techniques for evaluating drug value 2023 11 2 91 8
/content/journals/cdrr/10.2174/0125899775394503250626070441
Loading
/content/journals/cdrr/10.2174/0125899775394503250626070441
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test